Drug pipeline IP, compound libraries, molecular data, and proprietary formulations represent years of investment and are prime targets for nation-state actors and corporate espionage. We assess AI and ML-driven drug discovery platforms for model integrity and data governance, review bioinformatics and computational biology environments, and evaluate LIMS, biorepository, and connected lab equipment security. Genomics England, UK Biobank, and broader -omics data environments require specific security posture reviews given the sensitivity of the data they hold. Collaborative research platforms used with university partners across the Golden Triangle (London, Oxford, Cambridge), Innovate UK-funded projects, Catapult Centres, and NIHR data sharing arrangements all expand the attack surface into less mature security environments. We assess these partnerships for cyber governance, access controls, and data loss prevention.

Clinical trial data is among the most sensitive in any sector. Compromised trial data can invalidate years of research and delay drug approvals by years. We assess Electronic Data Capture systems, Clinical Trial Management Systems, and Randomisation and Trial Supply Management (RTSM/IRT) security. eClinical platform risk assessments cover Medidata, Veeva, and Oracle Health Sciences. Decentralised clinical trial platforms, Patient-Reported Outcomes (ePRO/eCOA) applications, and Real-World Evidence data sources including the Clinical Practice Research Datalink all carry distinct security requirements. NHS DigiTrials and digital trial platform security is relevant where trials run through NHS infrastructure. We assess investigator site security and third-party risk at NHS Trust trial sites, pharmacovigilance and Yellow Card reporting system security, and HRA (Health Research Authority) compliance. Our work aligns with ICH E6 R2/R3 GCP data integrity requirements, ALCOA+ principles, and UK GDPR Article 9 special category data handling including de-identification and pseudonymisation of clinical data.

Security testing in GxP environments must be non-disruptive and validated. We help pharmaceutical organisations align with MHRA GxP (GMP, GLP, GCP), MHRA Data Integrity Guidance, MHRA Annex 11, and the Orange Guide. For firms exporting to the US, FDA 21 CFR Part 11 readiness for electronic records and signatures is essential. GAMP 5 alignment ensures risk-based validation of computerised systems with appropriate cyber controls. UK GDPR, DPA 2018, NIS Regulations, and upcoming UK NIS2-equivalent legislation all apply. We support NCSC Cyber Assessment Framework alignment, NHS DSPT submissions where pharma intersects NHS, and ICO Accountability Framework and DPIA guidance. For LSE-listed pharmaceutical companies, UK Corporate Governance Code cyber risk reporting and FCA Listing Rules cyber disclosure requirements add board-level obligations. Dual-listed UK/US firms may also need SEC cybersecurity disclosure alignment. Compliance is the baseline. Operational resilience is the goal.

The pharmaceutical supply chain is one of the most complex in any industry. CRO cyber risk assessments, CDMO and CMO security reviews, and API (Active Pharmaceutical Ingredient) supplier vetting form the core of our third-party work. Academic research partners, Innovate UK-funded collaborations, and licensing partner governance all expand exposure into environments with varying security maturity. Logistics, distribution, and cold chain partner risk management covers UK-specific wholesaler networks and temperature-sensitive product integrity. We assess third-party SaaS and cloud vendors, MSPs and IT outsourcing partners, and alignment with Crown Commercial Service frameworks where pharma engages with NHS or public sector. M&A cybersecurity due diligence and divestiture or carve-out cyber risk advisory protects organisations during corporate transactions. Serialisation networks under the Falsified Medicines Directive require ongoing integrity assurance. Concentration risk where multiple pharma companies share the same CDMO or CRO is a specific concern we assess and report on.

The pharmaceutical industry is shifting to cloud at pace but the migration creates risk. We conduct cloud security posture reviews for pharma workloads on Veeva Vault, SAP, AWS London and EU regions, and Azure UK. UK data residency and sovereign cloud advisory ensures patient and clinical data stays within appropriate jurisdictions. SaaS application assessments cover Veeva, IQVIA, and Medidata. Digital Lab and Lab of the Future environments introduce connected instruments and IoT devices into research workflows. ERP security reviews cover SAP S/4HANA deployments in pharma. Digital twin and simulation environments used in drug development carry their own data integrity risks. We advise on Zero Trust architecture, Identity and Access Management strategy for GxP systems, and NCSC Cloud Security Principles alignment. The persistent challenge is that cutting-edge AI drug discovery tools sit alongside 15-year-old legacy systems running critical manufacturing hardware, and security during the co-existence phase is when exposure peaks.

Biotech startups in the Golden Triangle ecosystem often carry high IP value with lower security maturity. We deliver cybersecurity maturity assessments proportionate to their stage and risk profile. Gene and cell therapy data security is a growing area given the UK's position as a global hub through the CGT Catapult. Biorepository and biobank system protection covers UK Biobank and Genomics England data environments. LIMS, Chromatography Data Systems, and instrument data integrity assessments address the connected laboratory. Medical device development lifecycle security aligns with MHRA, UK MDR 2002, and FDA 524B for US market access. Companion diagnostics platform security and mRNA or biologics manufacturing OT security are emerging areas. Vaccine manufacturing and pandemic preparedness cyber resilience draws on lessons from the UK COVID response.